Inside PIC/S: Implementing Quality Risk Management - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside PIC/S: Implementing Quality Risk Management
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.

Pharmaceutical Technology
Volume 33, Issue 12

Implementing the methodology

The PIC/S example of methodology provides pharmaceutical manufacturers with the means, including training tools and a starter kit, to implement quality risk management. The methodology relies on an interactive database that is accessible to industry.

Figure 1: Diagram of a sample operation in service. CAPA is corrective and preventive action. QRM is quality risk management. GMP is good manufacturing practice. (FIGURE 1 IS COURTESY OF THE AUTHORS)
This service, expected to be available soon, will be hosted and maintained on an independent platform that brings together industry, professional associations, and other pharmaceutical manufacturing partners. Drug manufacturers will be able to voluntarily integrate the system on a customer-supplier basis (see Figure 1).

The platform will make available the assistance necessary to implement the method, guarantee confidentiality, and use the information supplied exclusively for implementing the risk-management methodology.

Future prospects

The informal PIC/S working group has performed beta-tests on the proposed methodology. The methodology will, however, need to be placed under change-control management to achieve continuous improvement.

PIC/S will finalize and implement the example of methodology, possibly by the end of 2010.

Read more about the Pharmaceutical Inspection Cooperation Scheme at and

Lionel Viornery is an inspector and head of the starting materials inspection unit at the French Health Products Safety Agency (Afssaps), 143/147, bd Anatole, Saint Denis cedex, 93285, France,
. Philippe Legoff is managing director of H&LG Consultants, Biolleyre 5, CH-1066 Epalinges, Switzerland,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here